Chronic Pain, Opioid Use, and Epidermal Nerve Fiber Density
COED
Chronic Opioid Use and Epidermal Nerve Fiber Density
1 other identifier
observational
38
1 country
1
Brief Summary
This pilot study is being performed to examine whether epidermal axons are altered in patients taking opioid therapy for chronic non-cancer pain, and if epidermal axonal changes predict heightened pain sensitivity.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Dec 2020
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 7, 2020
CompletedFirst Submitted
Initial submission to the registry
March 11, 2021
CompletedFirst Posted
Study publicly available on registry
March 17, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 25, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
June 25, 2024
CompletedNovember 6, 2024
November 1, 2024
3.6 years
March 11, 2021
November 4, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
IENFD
Intraepidermal Nerve Fiber Density
Baseline
Secondary Outcomes (16)
Fibromyalgianess
Baseline
Clinical Pain Severity
Baseline
Neuropathic Pain Descriptors
Baseline
Stress
Baseline
Catastrophizing
Baseline
- +11 more secondary outcomes
Study Arms (3)
Healthy controls
Men and women ages 18-65 years old with no major medical problems and no history of chronic pain or opioid use.
Chronic pain patients not taking opioids
Diagnosis of non-cancer chronic pain syndrome (persistent pain lasting longer than 3 months) that have not used any opioid medication within the past one year.
Chronic pain patients taking opioids
Diagnosis of non-cancer chronic pain syndrome (persistent pain lasting longer than 3 months) using chronic daily opioid use for longer than 3 months duration and taking stable doses of opioid medications for at least 30 days prior to study visit.
Eligibility Criteria
A cross-sectional study will recruit a total of 60 men and women in three cohorts (20 each): 1) chronic non-cancer pain patients who are utilizing long-term (greater than 3 months of daily use) opioid medication to treat their chronic pain conditions, 2) chronic non-cancer pain patients who do not take opioid medications, and 3) healthy controls.
You may qualify if:
- Healthy/All:
- Informed consent provided by the participant
- Able to read and speak in English
- Age 18 to 65 years
- Likely to participate in all scheduled evaluations and study procedures
- IF they are a Chronic Non-Cancer Patients who do NOT take opioid medication they must meet all of the above criteria as well as:
- Diagnosis of non-cancer chronic pain syndrome (persistent pain lasting longer than 3 months)
- IF they are a Chronic Non-Cancer Patients who DO take opioid medication they must meet all of the above criteria as well as:
- Chronic daily opioid use for longer than 3 months duration
- Stable doses of opioid medications for at least 30 days prior to study visit
You may not qualify if:
- Pregnancy
- Prisoner
- Current clinically significant cardiac, or neurologic disease
- Significant skin disorders in lower extremities
- Circulatory insufficiency
- Open wounds in lower extremity that may interfere with healing
- Lidocaine allergy
- Currently taking anticoagulation (e.g., Coumadin, Plavix, etc)
- Current litigation for chronic pain
- Active psychotic or suicidal symptoms
- Current drug or alcohol abuse
- Neuropathy in upper extremities (hands specifically, PI discretion).
- Current or recent use of artificial fingernails or nail enhancements (last 6 months)
- Other diagnoses that are not considered minor/stable (PI discretion)
- Current or previous cancer diagnosis
- +3 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Kansas Health System
Kansas City, Kansas, 66160, United States
Biospecimen
Cheek swab
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Andrea L Chadwick, MD, MSc, FASA
University of Kansas School of Medicine
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
March 11, 2021
First Posted
March 17, 2021
Study Start
December 7, 2020
Primary Completion
June 25, 2024
Study Completion
June 25, 2024
Last Updated
November 6, 2024
Record last verified: 2024-11